AAI Names Science Immunology Founding Editor as Its First Scientific Programs Chief
Announcement from the American Association of Immunologists (AAI). Appointment effective March 25, 2026.
When Science Immunology launched in 2016, it needed someone to build a journal from scratch in a field that was about to become one of the most consequential in medicine. The person who took on that task was Anand Balasubramani. Within a few years, the journal had established itself as a leading publication in the field.
Now Balasubramani is taking on another building project. The American Association of Immunologists (AAI) has appointed him as its inaugural Chief Scientific Programs Officer (CSPO), effective March 25, 2026. The newly created position signals the organization's intent to expand its scientific programming, publications, and educational initiatives at a time when immunology itself is expanding rapidly beyond traditional boundaries.
From journal builder to organizational strategist
Balasubramani's career has centered on the infrastructure of scientific communication. After his founding role at Science Immunology, he moved to the American Society for Microbiology, where he served as Journals Development Editor. In that role, he led the launch and growth of high-volume journals and built strategic initiatives and partnerships to advance the society's scientific mission.
His scientific background includes research in autoimmunity, cytokine biology, epigenetics, and leukemia -- a breadth that spans the increasingly diverse territory of modern immunology.
At AAI, Balasubramani will serve on the senior leadership team, overseeing the association's publications, education, and scientific affairs portfolios. He will lead strategic initiatives and work with AAI staff, Council, and members to ensure the organization's programming reflects the expanding scope of immunology, from fundamental discovery to clinical translation.
Why the role exists now
The creation of the CSPO position reflects a broader trend among scientific societies: the recognition that scientific programming needs dedicated executive leadership, not just committee oversight. As immunology has grown from a focused academic discipline into a field with direct clinical impact -- cancer immunotherapy, vaccine development, autoimmune disease management -- the demands on a professional society have grown correspondingly.
AAI is one of the world's largest organizations of immunologists, and its members have been responsible for many of the most important biomedical advances of the past century, including cancer immunotherapies, antibody therapies, transplant technologies, and vaccines. Maintaining relevance to a membership that now spans basic researchers, translational scientists, and clinicians requires programming that serves all three constituencies.
Loretta Doan, AAI's Chief Executive Officer, described Balasubramani as uniquely suited for the role, citing his deep roots in the immunology community, leadership in scientific publishing, and strong strategic vision. She noted that AAI is confident he will help expand the organization's impact during a period of significant growth for both the field and the organization.
The expanding boundaries of immunology
Balasubramani acknowledged the breadth of modern immunology in his statement about the appointment, describing the discipline as spanning discovery science, translational innovation, and therapies that are transforming patient care. He expressed interest in building programs that support the expanding community of scientists, clinicians, and healthcare professionals working in immunology.
That expansion is not merely rhetorical. Checkpoint inhibitor immunotherapies have transformed cancer treatment. CAR-T cell therapies have produced durable remissions in previously incurable blood cancers. mRNA vaccine platforms, accelerated by the COVID-19 pandemic, are being adapted for influenza, RSV, and other infectious diseases. Each of these advances draws on immunological principles and creates demand for education, programming, and professional development that a society like AAI is positioned to provide.
What remains to be seen
The appointment is an organizational move, not a scientific finding, and its success will be measured over years rather than in a single publication cycle. Whether the CSPO role will lead to meaningfully different programming, increased membership engagement, or expanded international collaborations will depend on execution rather than intent.
Scientific societies broadly face challenges that no single hire can solve: competition for member attention from online platforms, pressure on the traditional journal publishing model, and the difficulty of serving a membership with increasingly diverse professional needs. Balasubramani's publishing experience positions him well for some of these challenges but not all of them.
The role will also require navigating the tension between serving established immunologists and attracting the next generation of researchers, who may have different expectations for professional societies, different career trajectories, and different needs from scientific programming.
AAI noted that Balasubramani will play a key role in shaping new initiatives, supporting international collaborations, and advancing priorities highlighted in the AAI Strategic Framework. The specifics of those initiatives will determine whether the creation of the CSPO role marks a genuine strategic shift or a primarily symbolic one.